ArticleScientific reports2025
Allostatic load and risk of prostate cancer in UK Biobank.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Allostatic Load Predicts Symptom Burden Among Breast Cancer Survivors.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Allostatic load (AL), a biomarker of chronic stress, has been implicated in the carcinogenesis of various types of cancers. However, its role in the etiology of prostate cancer is unclear. Utilizing valuable resources from the UK Biobank, we analyzed the association between AL and subsequent risk of prostate cancer in a total of 161,964 men. Levels of AL were higher in cases than in non-cancer controls (3.47 vs. 3.35, P < 0.001). In the univariate analysis, one unit increase in AL was associated with a 5% increased risk of prostate cancer (hazard ratio (HR) = 1.05, 95% Confidence Interval (CI) 1.03, 1.06). In the multivariate Cox regression analysis, the significant association was only observed among men younger than 58 years old. The significant association was further confirmed in the categorical analysis, and compared to men with AL of 0, those with AL of 1, 2, 3, 4, 5, and ≥ 6 had a statistically significantly increased risk of prostate cancer, respectively. Additionally, we observed a more than additive joint effect between AL and polygenic risk score (PRS) of prostate cancer among younger men (< 58 years old). In summary, those findings have shown that higher AL was associated with an increased prostate cancer risk in younger men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.